Patient-oriented Randomized Pragmatic Feasibility Trial with RTMS in Depression and Anxiety

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 11, 2021

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2025

Conditions
Major Depressive EpisodeMajor Depressive Disorder
Interventions
DEVICE

Repetitive Transcranial Magnetic Stimulation

rTMS will employ the MagPro X100 stimulator equipped with the cool-B70 coil (MagVenture, Farum, Denmark). The dose will be a 120% resting motor threshold (rMT) in accordance to our latest trial using iTBS. Localization of the right and left DLPFC will follow the well-established Beam F3 procedure. Subjects will then undergo 30 sessions of rTMS, once daily on weekdays for 6 weeks. FDA-approved iTBS protocol will consist of bursts of 3 pulses at 50 Hz, bursts repeated at 5 Hz for 600 pulses total, 2 s on, 8 s off, for 3 min 9 sec, at 120% rMT. LFR will consist of 1 Hz stimulation consisting of a single train of 10min duration for 600 pulses total at 120% rMT.

Trial Locations (1)

V6T 2A1

RECRUITING

Non-Invasive Neurostimulation Therapies (NINET) Laboratory, UBC Department of Psychiatry, Vancouver

All Listed Sponsors
lead

University of British Columbia

OTHER